Lyra Therapeutics(LYRA) - 2025 Q1 - Quarterly Results

The ENLIGHTEN program consists of two pivotal Phase 3 clinical trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR‑210 for the treatment of CRS. Each ENLIGHTEN trial enrolled approximately 180 CRS patients who have failed medical management and have not had prior ethmoid sinus surgery, randomized 2:1 to either LYR‑210 (7500µg mometasone furoate) or sham control for 24 weeks. Planned Reverse Stock Split Exhibit 99.1 Lyra Therapeutics Reports First Quarter 2025 Financial Results an ...